Ribonucleotide reductases: radical enzymes with suicidal tendencies  by Stubbe, JoAnne & van der Donk, Wilfred A.
JOANNE STUBBE AND WILFRED A VAN DER DONK REVIEW 
Ribonucleotide reductases: radical enzymes with 
suicidal tendencies 
Ribonucleotide reductases catalyze a key step in DNA biosynthesis, using a diverse 
array of unprecedented metallo-cofactors to generate a transient protein radical that 
initiates nucleotide reduction. The new understanding of the chemistry and 
biochemistry of the system has allowed rational design of inhibitors of this process, 
which function as antitumor and antiviral agents. 
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Ribonucleotide reductases (RNRs) catalyze the conver- The RNR isolated from bacteria grown under aerobic 
sion of nucleotides to deoxynucleotides, providing the conditions is prototypical of the class I RNRs, which 
monomeric precursors required for DNA biosynthesis also include mammalian and herpes simplex virus 
and DNA repair. These enzymes are unusual for a (HSV) RNRs. It is composed of two homodimeric 
number of reasons. First, they have very broad substrate subunits, Rl and R2. R2 contains the cofactor, which 
specificity and can catalyze the reduction of purine and is composed of an unusual k-oxo-bridged diferric 
pyrimidine nucleotides. Since maintenance of the relative cluster adjacent to a tyrosyl radical (*Tyr122 in 
ratios of dNTP pools is essential for the fidelity of DNA Escherichiu coli) [4]. The tyrosyl radical is essential for 
replication, they are allosterically regulated in a sophisti- catalysis, and is generated by the diferrous form of R2 
cated and incompletely understood fashion [1,2]. in the presence of 0, [5,6]. 
Second, despite the central role of RNRs in nucleotide 
metabolism, implying that they should be well con- The RNR isolated from Luctobacilltrs leichmannii (class II), 
served, their primary and quaternary structures are in contrast, is a monomer that uses adenosylcobalamin 
diverse. Third, the cofac:tors required for the reduction (AdoCbl = coenzyme B,,) as a cofactor.This enzyme has 
process, structurally and chemically, have also not been been the most extensively studied of the AdoCbl-requir- 
evolutionarily conserved (Fig. 1). At present there are ing RNRs [7]. Recent studies indicate that the function 
four classes of reductases, three of which have been and ofAdoCb1 is to generate a thiyl radical that is essential for 
continue to be under intense investigation [3]. the nucleotide reduction process [8]. 
Fig. 1. RNRs use a wide range of cofac- 
tors. The cofactors used by the four major 
classes of RNRs are shown. Although 
chemically diverse, it seems likely that 
each of these cofactors can be used to 
help form a thiyl radical (center), which 
is essential for catalysis in at least two, 
and probably all four, classes of RNRs. 
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The RNR isolated from E. coli grown under anaerobic 
conditions (class III) is distinct from the enzyme pro- 
duced under aerobic conditions. When isolated, it 
proved to have an essential glycyl radical which is gener- 
ated by an ‘activating enzyme’ [9], perhaps the second 
subunit of the enzyme, equivalent to R2 in the aerobic 
E. coli RNR.The activating enzyme requires S-adenosyl- 
methionine and an iron-sulfur cluster to generate the 
glycyl radical via a novel mechanism [lo]. 
The RNR from Brevibacteriwn ammoniagenes (which we 
consider as class IV) has been characterized by Follmann 
and coworkers [l l] and is thought to possess 01&l subunit 
structure and a dinuclear Mn3+ cluster analogous to the 
diferric cluster of aerobic E. coli RNR. Although it seems 
plausible that this enzyme, like all the other RNRs so far 
investigated, uses a protein radical for catalysis, this point 
has not yet been established. 
Despite the dramatic differences in these reductases 
(Fig. l), their mechanisms for nucleotide reduction (at 
least for classes I-III) are similar, and unusual, involving 
exquisitely controlled radical-based chemistry. Each of 
the metallo-cofactors initiates this radical-dependent 
nucleotide reduction process by generating a transient 
protein radical. The working model at present, based 
on the two best characterized RNRs, those from E. coli 
and L. leichmannii, is that the function of both the 
tyrosyl radical (in E. coli) and the adenosylcobalamin 
(in L. Zeichmaunii) is to generate a thiyl radical [12]. 
Many excellent reviews have been published on all 
aspects of RNRs in the past few years [2,3,5,7,13]. 
Here, we will focus on the new ideas on the catalytic 
mechanism obtained from studies using site-directed 
mutagenesis, mechanism-based inhibitors and struc- 
tural techniques. As the diferric-tyrosyl radical requir- 
ing reductases (class I RNRs) are potentially attractive 
targets for the design of antitumor and antiviral agents, 
this new information has led to a number of different 
approaches to inhibitor design. 
Background 
The sequences of a growing number of class I RNRs are 
available. There are 49 residues that are completely or 
strongly conserved in all 23 known sequences of the 
87-kDa Rl protomer, and 21 residues conserved in the 
24 known sequences of the 43.5-kDa R2 protomer. The 
X-ray structures of Rl and R2 from E. coli have also been 
reported [14,15]. The structural studies and sequence 
alignments, in conjunction with chemical and biochemi- 
cal studies, have provided us with a generic picture of 
class I RNRs (Fig. 2).The ‘business end’ of the molecule is 
the Rl subunit. It contains binding sites for the purine 
and pyrimidine diphosphate substrates and for the dNTPs 
and ATP, which act as allosteric effecters. In addition it 
contains five cysteines that are essential for catalysis [16]. 
Cysteines 225 and 462 are oxidized to form a disultide 
during nucleotide reduction, thus providing the required 
reducing equivalents [17,18]. Cys754 and Cys759 are at 
the carboxy-terminal tail of Rl, and are not detectable in 
the X-ray structure due to thermal flexibility.They shuttle 
reducing equivalents into and out of the active site via 
disulfide interchange with thioredoxin (one of several 
reductants present in vivo). The fifth cysteine, Cys439, is 
proposed to initiate nucleotide reduction by 3’-hydrogen 
atom abstraction [19]. 
The R2 subunit contains the diferric iron center and the 
tyrosyl radical essential for the reduction process [4,20]. 
This cofactor is buried in R2, lying 10 A from the 
nearest surface [15]. Reduction of the tyrosyl radical to 
tyrosine results in complete loss of nucleotide reduction 
capabilities. It is proposed that the tyrosyl radical gener- 
ates the thiyl radical on Cys439 of Rl, which (based on 
docking of the two available structures [14]) is some 
35 A away, thus initiating the nucleotide reduction 
ATP, dATP binding site 
controls reactivrty 
dNTP allosteric- 
effector bindin site 
controls specl rcty -P 
Fig. 2. Generic picture of the class I RNRs, 
based on extensive biochemical studies 
[71, and on docking of the two available 
X-ray crystal structures of Rl and R2 of the 
aerobic enzyme from E. co/i [I 4,151. The 
tyrosyl radical on R2 is proposed to gen- 
erate a thiyl radical at Cys439,35 A away, 
via an unknown mechanism. 
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process. The mechanism of communication between 
these subunits is a major focus of investigation. 
The most recent proposal [16] for a generic nucleotide 
reduction mechanism is shown in Figure 3.The key steps 
involve cofactor-mediated formation of a transient thiyl 
radical which initiates the nucleotide reduction process 
by abstracting the 3’-hydrogen atom. After loss of H,O, 
the two cysteines on the o-face of the nucleotide 
(Cys462, Cys225) d e iver the required reducing equiva- 1’ 
lents, generating a 3’-ketodeoxynucleotide and a c&sulfide 
radical anion. This intermediate is subsequently reduced 
to give dNDP and a disulfide, regenerating the thiyl 
radical. The essential metallo-cofactor, the interactions 
between the two subunits of the class I RNRs and the 
unusual radical intermediates in the nucleotide reduction 
process have all provided proven targets for design of 
inhibitors of this essential enzyme. 
Inhibitors of diferric-tyrosyl radical dependent RNRs 
Three potentially complementary approaches have suc- 
cessfully targeted RNR in vivo, based on the detailed 
understanding of the biochemistry of this system and of 
nucleotide metabolism. One involves nucleotide analogs 
as mechanism-based inhibitors. A second involves reduc- 
tion of the essential tyrosyl radical required for nucleotide 
reduction. The third focuses on inhibition of the interac- 
tion of the Rl and R2 subunits, both of which are 
required for nucleotide reduction. All three approaches 
have led to compounds used clinically or in clinical trials. 
Nucleotide inhibitors requiring S’xarbon-hydrogen 
bond cleavage 
The first approach, using nucleotide analogs as inhibitors, 
has provided considerable insight into the catalytic capabil- 
ities of RNRs and has also shown promise in generation of 
antitumor agents that may be clinically useful [21]. Both 
gemcitabine (2’,2”-difluorodeoxycytidine, dFdC) [22,23] 
and (E)-2’-methylenefluoro-2’-deoxycytidine ((I!+FMC) 
[24,25] are now in clinical trials for the treatment of solid 
tumors of the breast and prostate.The requirement that the 
RNR inhibitor must be a nucleotide, but the therapeuti- 
cally administered drug must be a nucleoside (because 
nucleotides are unable to penetrate the cell membrane) 
combined with the complexity of nucleotide metabolism 
raises the concern that drugs of the this kind could inter- 
fere in a multitude of metabolic pathways and lead to 
unwanted cytotoxic effects. Despite the potential problems, 
these compounds appear to be promising. 
Inhibitors of RNR can be used synergistically with 
DNA chain terminators targeting DNA polymerase 
[26]. This is easy to rationalize; inhibition of RNR 
decreases the amounts of dNDPs produced, and there- 
fore decreases the amounts of dNTPs (the substrates for 
the polymerase) available (Fig. 4). Nucleotide chain ter- 
minators (NTP analogs) will then be used more often 
by the polymerase, because of the decreased competition 
from the normal substrates. For cytidine nucleotide 
analogs, a second pathway may further potentiate the 
inhibition of DNA synthesis. DeoxyCTP has been 
reported to be an end-product inhibitor of deoxycyti- 
dine kinase (dCK), although its potency in vivo has been 
the subject of some debate [27-291. Decreases in levels 
of dCTP should therefore increase the activity of the 
kinase, thus increasing the conversion of cytidine analogs 
into the active di- and tri- phosphate forms. 
In 1976 Thelander, E&stein and coworkers [30] reported 
that 2’-chloro-2’-deoxynucleotides such as ClCDP and 
Fig. 3. Proposed mechanism for 
nucleotide reduction by RNRs. A tran- 
sient thiyl radical (red) initiates the 
nucleotide reduction process by 
abstracting the 3’-hydrogen atom (green) 
from the nucleoside diphosphate. H,O 
is lost, and the two cysteines on the 
a-face of the nucleotide then deliver the 
required reducing equivalents, gener- 
ating a 3’-ketodeoxynucleotide and a 
disulfide radical anion. This intermediate 
is subsequently reduced to give dNDP 
and a disulfide and to regenerate the 
thiyl radical. 6, base. 
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2’-azido-2’-deoxynucleotides, such as N,CDP, were 
potent inactivators of E. coli RNR. A detailed under- 
standing of the mechanism by which these compounds 
inactivate the enzyme has evolved since their discovery 
[7]. It was the insights gained from these studies that led 
McCarthy and coworkers [25,31] to design (I?)-FMC as 
a potent, specific inhibitor of RNR. 
A generalized view of the mechanism responsible for 
enzyme inactivation by nucleotide analogs is shown in 
Figure 5. The initial step, as in the case of NDP reduc- 
tion, is 3’-hydrogen atom abstraction by a thiyl radical. 
Deprotonation of the 3’-hydroxyl concomitant with 
removal of the leaving group, X, results in formation of a 
2’-deoxy-3’-ketonucleotide radical which can then be 
reduced from the top face (B-face) or the bottom face 
(o-face) of the inhibitor. Reduction from the bottom 
face results ultimately in the inability to regenerate the 
thiyl radical on Cys439 and hence, in the case of the 
E. coli RNR, the tyrosyl radical cannot be re-formed. A 
3’-ketodeoxynucleotide is also generated; its fate will be 
discussed below. Since the tyrosyl radical is essential for 
catalysis, inactivation of R2 is a major mechanism of 
RNR inhibition by many nucleotide mechanism-based 
inhibitors. If reduction occurs from the top face, 
however, the thiyl radical on Cys439, and hence the 
tyrosyl radical, is regenerated along with production of 
the same putative 3’-ketodeoxynucleotide. The subtle 
differences in protonation state of the cysteines in the 
active site during inactivation by these inhibitors, com- 
pared to their state during the normal reduction process 
(compare Fig. 3 with Fig. 5) causes the 3’-ketodeoxy- 
nucleotide to dissociate into solution. This compound 
then chemically decomposes to generate PPi, free 
nucleic-acid base and 2-methylene 3(2H) furanone [7]. 
The last of these inactivates RNR by nonspecific alkyla- 
tion of the Rl subunit. Incubation of [2’-3H] and [3’- 
3H]-2’-chlorodeoxy nucleotides with RNRs, followed by 
trapping of the intermediate 3’-ketodeoxynucleotide 
with NaBH4 and analysis of the stereochemistry of the 
products at C2’, has established that reduction can occur 
from either face of the nucleotide [7,32]. These results 
showed that a given nucleotide analog inhibitor can use 
two different mechanisms for enzyme inactivation. The 
partitioning between Rl and R2 inactivation depends 
on the nucleotide analog, the allosteric effector and the 
reducing system present in a subtle way, which is incom- 
pletely understood. The results from studies with a 
variety of mechanism-based inhibitors can be accounted 
for by this paradigm (Fig. 5), accompanied, as outlined 
below, by a few additional twists that have interesting 
mechanistic implications (Fig. 6). 
Understanding the mechanism of inhibition 
Inactivating one molecule of E. colt’ RNR requires 1.5 
equivalents of N,UDP Enzyme inactivation is accom- 
panied by rapid loss of the essential tyrosyl radical on 
R2 and production of N, (Fig. 6a), initiated by 3’- 
hydrogen atom abstraction [30,33]. Loss of the essential 
tyrosyl radical occurs concomitant with rapid formation 
of a new nitrogen-centered radical [34,35], which 
recent studies have shown to be covalently attached to 
Cys225 and probably to the 3’-ketodeoxynucleotide 
generated during the inactivation event [36]. Ultimately 
the nitrogen-centered radical disappears (with a t1,2 of 
20 min) and is accompanied by the generation of 
pyrophosphate, nucleic acid base, and the furanone 
(compound 1, Fig. 6), which stoichiometrically alky- 
lates Rl [33].The evidence that HN, is released before 
the formation of N, and the nitrogen-centered radical 
dUDP -- dTTP 
dGDP -W dGTP 
dADP _* dATP 
dCDP _ 
chain terminator 
f-________ XdCDP A XdCTP 
UDP 
GDP 
ADP 
CDP 
XdCMP ; 
deoxycytidine analog 
Fig. 4. Summary of nucleoside metabo- 
lism pathways. Nucleoside diphosphates 
are reduced by RNRs to deoxynucleoside 
diphosphates, then phosphorylated to the 
corresponding triphosphates, which are 
used as substrates for DNA polymerase. 
Inhibitors of RNRs reduce the available 
pool of dNTPs, decreasing the competi- 
tion for nucleotide analog chain termina- 
tors and increasing their effectiveness. 
Inhibitors of dCTP production may also 
decrease feedback inhibition of deoxycy- 
tidine kinase (dCK). This increases phos- 
phorylation of deoxycytidine analogs, 
leading to increased production of the 
triphosphate, which inhibits DNA poly- 
merase. There are thus two mechanisms 
for RNR inhibitors to increase the effec- 
tiveness of deoxycytosine-based DNA 
polymerase inhibitors. 
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Fig. 5. Mechanism of inhibition of an 
RGR by a nucleotide analog. After 
abstraction of the 3’-hydrogen atom by 
the thiyl radical, the leaving group, X-, is 
lost generating a 3’-keto-2’-deoxynu- 
cleotide radical. This species can be 
reduced from either the p-face (top) or 
the a-face (bottom). If reduction occurs 
from the a-face, the thiyl radical cannot 
be regenerated and the enzyme is inacti- 
vated. Reduction from the p-face results 
in a 3’-ketodeoxynucleotide which dis- 
sociates from the active site and decom- 
poses to yield the 2-methylene-3(2H)- 
furanone, which non-specifically alky- 
lates the Rl subunit of the enzyme, inac- 
tivating it (this can be detected by 
absorbance at X = 320 nm). The factors 
that determine whether the reduction 
occurs from the top face or the bottom 
face are incompletely understood. 6, 
base; PPi, pyrophosphate. 
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is based on studies with a mutant Rl, in which Cys225 
is changed to a serine. With this mutant, tyrosyl radical 
is not lost and no nitrogen-centered radical is generated 
[37]. Only azide is detected. These observations provide 
support for the hypothesis that Cys225 is central in the 
conversion of the hydrazoic acid to N, and the cova- 
lently bound nitrogen radical species. The studies with 
this inhibitor support the proposal that reduction from 
the a-face of the nucleotide can proceed by an elec- 
tron-transfer mechanism and that RNR catalyzes 
radical-dependent reactions. 
A second intriguing observation has been made with 
this same site-directed mutant of Rl, Cys225+SerRl. 
This mutant uncouples 3’-carbon-hydrogen bond cleav- 
age from the nucleotide-reduction process. Incubation 
of CDP with Cys225+SerRl and R2 resulted in loss of 
the tyrosyl radical, and release of cytosine and pyrophos- 
phate ([38]; Fig. 6b). The inability to complete the 
nucleotide-reduction process, due to the mutation of 
Cys225, leads to cleavage of the Rl polypeptide into 
two pieces. The cleavage is stoichiometric with tyrosyl 
radical loss, suggesting that the fragmentation is a 
radical-based reaction. Recently, the site of cleavage has 
been established by mass spectroscopic analysis to be 
between Ser224 and Ser225 of the mutant enzyme 
(W.A. van der D., C. Zeng, K. Biemann, J.S., A. Hanlon, 
& J.E. Kyte,unpublished data). The Ser224 fragment 
does not have a carboxylate carboxyl terminus, but a 
carboxamide. Furthermore, Va1226 has a formyl group 
on its nitrogen (Fig. 6b). The fate of the remaining two 
carbons of Ser225 has not been defined. Although the 
chemistry of this process is unknown, these studies 
provide the first unambiguous identification of the 
active site of RNR. Moreover, the uncoupling of the 
nucleotide-reduction process from the 3’-hydrogen 
atom abstraction and the use of [3’-2H]-NDP have 
established that there is an isotope effect on tyrosyl 
radical reduction [38]. These studies provide the first 
direct evidence that the tyrosyl radical on R2 is involved 
in hydrogen-atom abstraction from the NDP on Rl, 
some 35 A away. 
A detailed understanding of the modes of inactivation of 
wild type RNR by ClNDP, N,NDP and of 
Cys225dSerRl by CDP has led to the design of a 
variety of mechanism-based inhibitors. One of the 
designed inhibitors, (I?)-FMCDP (Fig. 6c), is now in 
clinical trials [24,25]. Its mode of inactivation is similar to 
that described above with an interesting twist and a 
mechanistic bonus (W.A. van der D. et al., & E. Wagner, 
unpublished data). One and a half equivalents of 
FMCDP is sufficient for enzyme inactivation, which 
results from a partitioning between both Rl and R2 
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Fig. 6. Reactions of nucleotide analog inhibitors with RNR and 
RNR mutants. Brief descriptions are given of the reaction of (a) 
N,UDP with the wild-type aerobic f. co/i enzyme Rl R2; (b) 
CDP with the Cys225-6er Rl mutant and R2; (c) (&FMCDP 
with the wild-type Rl R2 enzyme (* indicates 14C label); and (d) 
dFdCDP with the wild-type enzyme. These reactions are further 
described in the text. 
inactivation. The tyrosyl radical is readily lost (Fig. 6c), a 
chromophore associated with Rl, detectable at wave- 
length 334 nm, rapidly appears, cytosine and fluoride 
ion are released and Rl is stoichiometrically labeled. 
Studies with a variety of site-directed Rl mutants 
suggest that the covalently modified residue is either 
Cys439 or Glu441. Efforts to identify a labeled peptide 
have been unsuccessful, but solid state NMR experi- 
ments are now in progress using [6’-13C]-FMCDP to 
determine whether an oxygen or a sulfur atom is 
attached to the labeled carbon. 
As in the cases of inactivation of wild type Rl by 
N,UDP and Cys225-+SerRl by CDP, loss of the tyrosyl 
radical is accompanied by formation of a second radical. 
Recent electron paramagnetic resonance spectroscopy 
studies of this reaction using [6’-2H]-(E)-FMCDP have 
demonstrated that the second radical is substrate-derived. 
A mechanism that accommodates all of the available data 
is shown in Figure 7. Preliminary results suggest that the 
stabilized 3’-radical intermediate (compound 2, Fig. 7) 
can be directly observed using this inhibitor, which 
would provide the first direct evidence for 3’-hydrogen 
atom abstraction from a nucleotide. 
Gemcitabine (dFdC) is another nucleoside analog which 
is presently being evaluated for clinical use against 
leukemias and solid tumors [22,23]. Studies on the 
metabolism of dFdC have indicated the possibility of 
self-potentiation via the synergistic mechanisms 
described above (Fig. 4) [39]. In vitro about four equiva- 
lents of dFdCDP are required to completely inactivate 
RNR from E. coli. The mode of inhibition is strongly 
dependent on the reaction conditions, and, although 
similar to the paradigm shown in Figure 5 (Fig. 6d), its 
mechanistic details have not been elucidated (R. 
Sanchez, G. Yu, W.A. van der D. and J.A.S, unpublished 
data). It is interesting that dFdCDP is the only mecha- 
nism-based inhibitor studied to date which does not 
produce an observable chromophore on Rl concomitant 
with Rl inactivation. 
Tyrosyl radical reduction 
The second approach to inhibitor design of Class I 
RNRs uses compounds such as hydroxyurea (HU) 
which has been shown to reduce the essential tyrosyl 
radical on R2, generating an oxidized HU radical [40]. 
HU does not bind to R2 and the X-ray structure of R2 
from E. coli has revealed that Tyr122, which is the 
residue that is ultimately reduced, is 10 A from the 
closest surface [15]. The mechanism by which this 
reduction occurs therefore remains a mystery. It is 
intriguing that the rate of HU-mediated reduction of 
the tyrosyl radical is potentiated by the Rl subunit in 
the presence of certain substrates/or effecters [41]. Since 
the communication between R2 and Rl, separated by 
-35 A, has been proposed to occur via a coupled elec- 
tron and proton transfer process, it could be that HU is 
intercepting an intermediate radical generated during 
this process. 
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Fig. 7. Proposed mechanism for RNR 
inhibition by (E)-FMCDP. Hydrogen 
abstraction from the 3’ carbon of the 
inhibitor proceeds normally. The radical 
intermediate (2) can be reduced from 
the bottom face (major pathway) or top 
face (minor pathway). In both cases a 
reactive enol is generated that can 
rapidly lose fluoride to generate an a,f3- 
unsaturated ketone activated towards 
nucleophilic attack. Because reduction 
occurs from the bottom face in the 
major pathway, the predominant mode 
of inactivation is from loss of the tyrosyl 
radical. C, cytosine. 
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HU has recently been claimed to potentiate the effect of 
AZT, the triphosphate of which inhibits the reverse tran- 
scriptase enzyme of human immunodeficiency virus, in 
the treatment of AIDS [42]. This is reminiscient of the 
effect of the nucleotide mechanism-based inhibitors of 
RNR on inhibitors of DNA polymerase, and the mech- 
anism is probably much the same. Although HU can 
clearly inhibit class I RNRs by reducing their essential 
tyrosyl radical, caution is warranted when considering 
this as a therapeutic target. Studies in E. coli by Reichard, 
Fontecave and coworkers [5,43] have shown that a flavo- 
doxin reductase and a unknown factor, in the presence 
of O,, can regenerate the tyrosyl radical after it has been 
reduced. It is not yet clear whether such a metabolic 
pathway exists in eukaryotic systems; it might, for 
example, regulate nucleotide reduction as a function of 
the cell cycle. It is possible, however, that efficient inacti- 
vation of RNR might require inhibition of a putative 
regeneration pathway as well. On the other hand, incom- 
plete inhibition may be ideal, since the activity of the 
mammalian enzyme is required for normal cell replica- 
tion and survival. 
Thiosemicarbazones [44] are also known to destroy the 
tyrosyl radical on R2 and may be placed in the same cat- 
egory of inhibitors with HU, although their mechanism 
of inactivation remains to be established. These com- 
pounds have recently been developed in conjunction 
with acyclovir (9-[(2-hydroxyethoxy)methyl]guanine, the 
triphosphate of which inhibits HSV polymerase) as topi- 
cally applicable HSV inhibitors [45,46]. 
Inhibition of subunit interactions 
Biochemical studies have established that the Rl subunit 
of RNR can be easily separated from the R2 subunit 
and more quantitative studies have revealed the K, for 
interaction of the subunits to be -0.18 FM for E. coli 
[47], and -0.17 p,M for mouse RNR [48]. This weak 
interaction provides a third approach to the design of 
inhibitors of RNRs. Dutia et al. [49] and Cohen et al. 
[50] observed with RNR from HSV-1 that the nine 
amino acids at the carboxy-terminal end of the R2 
subunit of this enzyme are the predominant source of 
binding energy between the two subunits. Studies on the 
mammalian [51] and E. coli RNRs [47] suggest that the 
carboxy-terminal tails of their respective R2 subunits 
provide the predominant source of interaction energy 
between subunits as well. Since the carboxy-terminal 
tails of all of these subunits have unique sequences, it 
might be possible to design specific inhibitors [52].The 
largest effort in drug design using this approach is from 
the group at Bio-mtga, targeting HSV-RNRs. They 
have recently designed a peptidomimetic of the carboxy- 
terminal tail of HSV R2, which inhibits nucleotide 
reduction both in vitro and in vim [53]. 
Despite the solution of the X-ray structure of E. coli R2, 
the conformation of the carboxy-terminal tail has been 
elusive as the X-ray structure did not detect the terminal 
30 amino acids. NMR analysis of mammalian R2 [54], 
HSV R2 (S.R. LaPlante, N.Aubry, N. Moss & M. Liuzzi, 
abstract, Keystone Symposium on Molecular and Cellular 
Biology, March, 1993) and, more recently, E. coli R2 [55] 
indicate that the carboxy-terminal tail is detectable using 
this method, as it tumbles at a rate different from the 
overall rate of globular R2, indicating that it is not folded 
as part of the globular domain but behaves as a distinct 
entity. A peptide corresponding to the carboxy-terminal 
tail of the E. coli R2 subunit allowed the successful crys- 
tallization of the Rl subunit, but only 8 of the 20 amino 
acids are apparently detectable [14]. Thus, although this 
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region of R2 is clearly important in interactions between 
the two subunits, more work will be required before the 
molecular details of the contacts between the subunits are 
understood. Design of inhibitors of essential subunit 
interactions could provide a new paradigm in drug 
design. Whether this approach is applicable to situations 
in which the inter-subunit interactions have an affinity 
higher than the sub-micromolar affinity of Rl for R2 
remains to be established, however. 
Summary 
Since the discoveries of RNRs in the 196Os, a wealth of 
knowledge has been obtained about the chemistry and 
biochemistry of these unusual metallo-proteins. The new 
frontiers will involve understanding the assembly and dis- 
assembly of the metallo-cofactors, the mechanism(s) of 
allosteric regulation which govern specificity and turnover, 
and the regulation at the transcriptional [56] and transla- 
tional levels and discovering how these proteins fit into the 
machinery involved in DNA replication and repair. 
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